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SUMMARY
We performed an extensive immunogenomic anal-
ysis of more than 10,000 tumors comprising 33
diverse cancer types by utilizing data compiled by
TCGA. Across cancer types, we identified six im-
mune subtypes—wound healing, IFN-g dominant,
inflammatory, lymphocyte depleted, immunologi-
cally quiet, and TGF-b dominant—characterized by
differences in macrophage or lymphocyte signa-
tures, Th1:Th2 cell ratio, extent of intratumoral het-
erogeneity, aneuploidy, extent of neoantigen load,
overall cell proliferation, expression of immunomod-
ulatory genes, and prognosis. Specific driver
mutations correlated with lower (CTNNB1, NRAS,
or IDH1) or higher (BRAF, TP53, or CASP8) leukocyte
levels across all cancers. Multiple control modalities
of the intracellular and extracellular networks (tran-
scription, microRNAs, copy number, and epigenetic
processes) were involved in tumor-immune cell inter-
actions, both across and within immune subtypes.
Our immunogenomics pipeline to characterize these
heterogeneous tumors and the resulting data are
intended to serve as a resource for future targeted
studies to further advance the field.
INTRODUCTION
TheCancer GenomeAtlas (TCGA) has profoundly illuminated the
genomic landscape of human malignancy. Genomic and tran-
scriptomic data derived from bulk tumor samples have been
used to study the tumor microenvironment (TME), and measures
of immune infiltration define molecular subtypes of ovarian,
melanoma, and pancreatic cancer (Bailey et al., 2016; The Can-
cer Genome Atlas Network, 2015; The Cancer Genome Atlas
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Research Network, 2011) and immune gene expression in other
tumors varies bymolecular subtype (Iglesia et al., 2016). Charac-
terization of the immune microenvironment using gene expres-
sion signatures, T cell receptor (TCR), and B cell receptor
(BCR) repertoire, and analyses to identify neo-antigenic immune
targets provide a wealth of information in many cancer types and
have prognostic value (Bindea et al., 2013; Brown et al., 2014,
2015; Charoentong et al., 2017; Gentles et al., 2015; Iglesia
et al., 2016; Li et al., 2016; Porta-Pardo and Godzik, 2016;
Rooney et al., 2015).
Contemporaneous with the work of TCGA, cancer immuno-
therapy has revolutionized cancer care. Antibodies against
CTLA-4, PD-1, and PD-L1 are effective in treating a variety of
malignancies. However, the biology of the immune microenvi-
ronment driving these responses is incompletely understood
(Hugo et al., 2016; McGranahan et al., 2016) but is critical to
the design of immunotherapy treatment strategies.
We integrated major immunogenomics methods to charac-
terize the immune tumormicroenvironment (TME) across 33 can-
cers analyzed by TCGA, applyingmethods for the assessment of
total lymphocytic infiltrate (from genomic and H&E image data),
immune cell fractions from deconvolution analysis of mRNA-
seq data, immune gene expression signatures, neoantigen pre-
diction, TCR andBCR repertoire inference, viral RNA expression,
and somaticDNAalterations (Table S1). Transcriptional regulato-
ry networks and extracellular communication networks that may
govern the TME were found, as were possible germline determi-
nants of TME features, and prognostic models were developed.
Through this approach, we identified and characterized six
immune subtypes spanning multiple tumor types, with potential
therapeutic and prognostic implications for cancer manage-
ment. All data and results are provided in Supplemental Tables,
at the NCI Genomic Data Commons (GDC, https://portal.gdc.
cancer.gov), and though the Cancer Research Institute iAtlas
portal for interactive exploration and visualization (http://www.
cri-iatlas.org), and are intended to serve as a resource for future
studies in the field of immunogenomics.
RESULTS
Analytic Pipeline
To characterize the immune response to cancer in all TCGA
tumor samples, identify common immune subtypes, and eval-
uate whether tumor-extrinsic features can predict outcomes,
we analyzed the TME across the landscape of all TCGA tumor
samples. First, source datasets from all 33 TCGA cancer types
and six molecular platforms (mRNA, microRNA, and exome
sequencing; DNA methylation-, copy number-, and reverse-
phase protein arrays) were harmonized by the PanCanAtlas
consortium for uniform quality control, batch effect correction,
normalization, mutation calling, and curation of survival data (Ell-
rott et al., 2018; Liu et al., 2018). We then performed a series of
analyses, which we summarize here and describe in detail in
the ensuing manuscript sections as noted within parentheses.
We first compiled published tumor immune expression signa-
tures and scored these across all non-hematologic TCGA cancer
types. Meta-analysis of subsequent cluster analysis identified
characteristic immunooncologic gene signatures, which were
then used to cluster TCGA tumor types into six groups, or
subtypes (described in Immune Subtypes in Cancer). Leukocyte
proportion and cell type were then defined from DNA
methylation, mRNA, and image analysis (see Composition of
the Tumor Immune Infiltrate). Survival modeling was performed
to assess how immune subtypes associate with patient prog-
nosis (see Prognostic Associations of Tumor Immune Response
Measures). Neoantigen prediction and viral RNA expression (see
Survey of Immunogenicity), TCR and BCR repertoire inference
(see The Adaptive Immune Receptor Repertoire in Cancer),
and immunomodulator (IM) expression and regulation (see
Regulation of Immunomodulators) were characterized in the
context of TCGA tumor types, TCGA-defined molecular
subtypes, and these six immune subtypes, so as to assess the
relationship between factors affecting immunogenicity and
immune infiltrate. In order to assess the degree to which
specific underlying somatic alterations (pathways, copy-number
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alterations, and driver mutations) may drive the composition of
the TME, we identified which alterations correlate with modified
immune infiltrate (see Immune Response Correlates of Somatic
Variation). We likewise asked whether gender and ancestry
predispose individuals to particular tumor immune responses
(see Immune Response Correlates of Demographic and Germ-
line Variation). Finally, we sought to identify the underlying intra-
cellular regulatory networks governing the immune response to
tumors, as well as the extracellular communication networks
involved in establishing the particular immune milieu of the
TME (see Networks Modulating Tumoral Immune Response).
Immune Subtypes in Cancer
To characterize intratumoral immune states, we scored 160 im-
mune expression signatures and used cluster analysis to identify
modules of immune signature sets (Figure 1A, top). Five immune
expression signatures—macrophages/monocytes (Beck et al.,
2009), overall lymphocyte infiltration (dominated by T andB cells)
(Calabro et al., 2009), TGF-b response (Teschendorff et al.,
2010), IFN-g response (Wolf et al., 2014), and wound healing
(Chang et al., 2004)—which robustly reproduced co-clustering
of these immune signature sets, were selected to perform cluster
analysis of all 30 non-hematologic cancer types (Figures 1A
middle, and S1A). The six resulting clusters ‘‘Immune Subtypes,’’
C1–C6 (with 2,416, 2,591, 2,397, 1,157, 385, and 180 cases,
respectively) were characterized by a distinct distribution of
scores over the five representative signatures (Figure 1A, bot-
tom) and showed distinct immune signatures based on the
dominant sample characteristics of their tumor samples (Figures
1B and 1C). Immune subtypes spanned anatomical location and
tumor type, while individual tumor types and TCGA subtypes
(Figures 1D and S1B–S1D) varied substantially in their proportion
of immune subtypes.
C1 (wound healing) had elevated expression of angiogenic
genes, a high proliferation rate (Figure 1C), and a Th2 cell bias
to the adaptive immune infiltrate. Colorectal cancer (COAD
[colon adenocarcinoma], READ [rectum adenocarcinoma]) and
lung squamous cell carcinoma (LUSC) were rich in C1, as were
breast invasive carcinoma (BRCA) luminal A (Figures S1C and
S1D), head and neck squamous cell carcinoma (HNSC) clas-
sical, and the chromosomally unstable (CIN) gastrointestinal
subtype.
C2 (IFN-g dominant) had the highest M1/M2 macrophage po-
larization (Figure S2A, mean ratio = 0.52, p < 10!149, Wilcoxon
test relative to next-highest), a strong CD8 signal and, together
with C6, the greatest TCR diversity. C2 also showed a high pro-
liferation rate, which may override an evolving type I immune
response, and was comprised of highly mutated BRCA, gastric,
ovarian (OV), HNSC, and cervical tumors (CESC).
C3 (inflammatory) was defined by elevated Th17 and Th1
genes (Figure 1C, both p < 10!23), low to moderate tumor cell
proliferation, and, along with C5, lower levels of aneuploidy
and overall somatic copy number alterations than the other
subtypes. C3 was enriched in most kidney, prostate adenocarci-
noma (PRAD), pancreatic adenocarcinoma (PAAD), and papillary
thyroid carcinomas (THCA).
C4 (lymphocyte depleted) was enriched in particular subtypes
of adrenocortical carcinoma (ACC), pheochromocytoma and
paraganglioma (PCPG), liver hepatocellular carcinoma (LIHC),
and gliomas, and displayed a more prominent macrophage
signature (Figure 2A), with Th1 suppressed and a high M2
response (Figure S2A).
C5 (immunologically quiet), consisted mostly of brain lower-
grade gliomas (LGG) (Figures 1D and S1B), exhibited the lowest
lymphocyte (p < 10!17) and highest macrophage (p < 10!7)
responses (Figure 2A), dominated by M2 macrophages (Fig-
ure S2A). Glioma subtypes (Ceccarelli et al., 2016) CpG island
methylator phenotype-high (CIMP-H), the 1p/19q codeletion
subtype and pilocytic astrocytoma-like (PA-like) were prevalent
in C5, with remaining subtypes enriched in C4. IDH mutations
were enriched in C5 over C4 (80% of IDH mutations, p < 2 3
10!16, Fisher’s exact test), suggesting an association of IDH
mutations with favorable immune composition. Indeed, IDH
mutations associate with TME composition (Venteicher et al.,
2017) and decrease leukocyte chemotaxis, leading to fewer
tumor-associated immune cells and better outcome (Amankulor
et al., 2017).
Finally, C6 (TGF-b dominant), which was a small group of
mixed tumors not dominant in any one TCGA subtype, displayed
the highest TGF-b signature (p < 10!34) and a high lymphocytic
infiltrate with an even distribution of type I and type II T cells.
These six categories represent features of the TME that largely
cut across traditional cancer classifications to create groupings
and suggest certain treatment approaches may be independent
of histologic type. For a complete list of the TCGA cancer type
abbreviations, please see https://gdc.cancer.gov/resources-
tcga-users/tcga-code-tables/tcga-study-abbreviations.
Composition of the Tumor Immune Infiltrate
Leukocyte fraction (LF) varied substantially across immune
subtypes (Figure 1C) and tumor types (Figure 2B). Tumors within
the top third LF included cancers most responsive to immune
checkpoint inhibitors, such as lung adenocarcinoma (LUAD),
LUSC, cutaneous melanoma (SKCM), HNSC, and kidney renal
clear cell carcinoma (KIRC), and in particular, the LUSC.secre-
tory, LUAD.6, bladder urothelial carcinoma (BLCA.4), kidney
renal papillary cell carcinoma (KIRP.C2a), and HNSCC mesen-
chymal subtypes. Uveal melanoma (UVM) and ACC had very
low LF. Glioma subtypes displayed a greater range in LF than
other tumors, which may reflect the presence or absence of
microglia.
The leukocyte proportion of tumor stromal fraction, r, varied
across tumor types and immune subtypes (Figures 2C and
S2B), ranging from >90% in SKCM to <10% in stroma-rich
tumors such as PAAD, PRAD, and LGG. Some tumors, e.g.,
BRCA, showed variation within annotated or immune subtypes.
In BRCA, C1 has the lowest r (rC1 = 0.44) while rC2 = 0.61 was
37% higher (p < 0.001) (Figure S2B), and there were likewise
differences between luminal A and basal BRCA (rLumA = 0.45
and rBasal = 0.67 [p < 0.001]). For LGG, rC5 = 0.28 (p < 0.001),
whereas rC3 = 0.48 and rC4 = 0.50 (p < 0.001) (Figure S2B),
and in READ, rCIN = 0.40 and rMSI = 0.78 (p < 0.001).
The spatial fraction of tumor regions with tumor-infiltrating
lymphocytes (TILs), estimated by analysis of digitized TCGA
H&E-stained slides (Saltz et al., 2018), varied by immune sub-
type, with C2 the highest (p < 10!16, Figure 2D). Image estimates
correlated modestly with molecular estimates of lymphocyte
proportion (Figures S2C and S2D), in part because themolecular




Figure 1. Immune Subtypes in Cancer
(A) Expression signature modules and identification of immune subtypes. Top: Consensus clustering of the pairwise correlation of cancer immune gene
expression signature scores (rows and columns). Five modules of shared associations are indicated by boxes. Middle: Representative gene expression
signatures from each module (columns), which robustly reproduced module clustering, were used to cluster TGCA tumor samples (rows), resulting in six immune
subtypes C1–C6 (colored circles). Bottom: Distributions of signature scores within the six subtypes (rows), with dashed line indicating the median.
(B) Key characteristics of immune subtypes.
(C) Values of key immune characteristics by immune subtype.
(D) Distribution of immune subtypes within TCGA tumors. The proportion of samples belonging to each immune subtype is shown, with colors as in (A). Bar width
reflects the number of tumor samples.
See also Figure S1 and Table S1.
4 Immunity 48, 1–19, April 17, 2018
estimate is more similar to cell count, while spatial TIL is a
fraction of the area. The relative similarity of the estimates of lym-
phocytic content between two radically different methodologies
reinforces the robustness of individual methods.
Prognostic Associations of Tumor Immune Response
Measures
Immune subtypes associated with overall survival (OS) and
progression-free interval (PFI) (Figures 3A and S3A). C3 had
the best prognosis (OS HR 0.628, p = 2.34 3 10!8 relative to
C1, adjusted for tumor type), while C2 and C1 had less favorable
outcomes despite having a substantial immune component. The
more mixed-signature subtypes, C4 and C6, had the least favor-
able outcome. Functional orientation of the TME for tumor and
immune subtypes was measured using the concordance index
(CI) (Pencina and D’Agostino, 2004) and found to have
context-dependent prognostic impact (Figures 3B, 3C and
S3B). Higher lymphocyte signature associated with improved
outcome in C1 and C2. An increased value of any of the five sig-
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Figure 2. Composition of the Tumor Immune Infiltrate
(A) The proportion of major classes of immune cells (from CIBERSORT) within the leukocyte compartment for different immune subtypes. Error bars show the
standard error of the mean.
(B) Leukocyte fraction (LF) within TCGA tumor types, ordered by median.
(C) LF (y axis) versus non-tumor stromal cellular fraction in the TME (x axes) for two representative TCGA tumor types: PRAD, (low LF relative to stromal content)
and SKCM (high leukocyte fraction in the stroma). Dots represent individual tumor samples.
(D) The spatial fraction of lymphocyte regions in tissue was estimated using machine learning on digital pathology H&E images (see also Saltz et al., 2018).
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reflecting a balanced immune response. While increased Th17
cells generally led to improved OS, Th1 associated with worse
OS across most immune subtypes, and Th2 orientation had
mixed effects (Figure 3C). Tumor types displayed two behaviors
relative to immune orientation (Figures 3B, OS; S3B, PFI). In the
first group including SKCM and CESC, activation of immune
pathways was generally associated with better outcome, while
in the other, the opposite was seen. The relative abundance of
individual immune cell types had complex associations that
differed between tumor types (Figures S3C and S3D). These an-
alyses extend beyond mere determination of lymphocyte pres-
ence to suggest testable properties that correlate with patient
outcome in different tumor types and immune contexts.
We obtained and validated a survival model using elastic-net
Cox proportional hazards (CoxPH) modeling with cross-valida-
tion. Low- and high-score tumors displayed significant survival
differences in the validation set (Figure 3D), with good prediction
accuracy (Figure 3E). Incorporating immune features into




Figure 3. Immune Response and Prognostics
(A) Overall survival (OS) by immune subtype.
(B) Concordance index (CI) for five characteristic
immune expression signature scores (Figure 1A) in
relation to OS, for immune subtypes and TCGA tu-
mor types. Red denotes higher and blue lower risk,
with an increase in the signature score.
(C) CI for T helper cell scores in relation to OS within
immune subtypes.
(D) Risk stratification from elastic net modeling of
immune features. Tumor samples were divided into
discovery and validation sets, and an elastic net
model was optimized on the discovery set using
immune gene signatures, TCR/BCR richness, and
neoantigen counts. Kaplan-Meier plot shows the
high (red) and low (blue) risk groups from this model
as applied to the validation set, p < 0.0001 (G-rho
family of tests, Harrington and Fleming).
(E) Prediction versus outcome from elastic net model
in validation set data (fromD). Top: Patient outcomes
for each sample (black, survival; red, death) plotted
with vertical jitter, along the sample’s model pre-
diction (x axis). Middle: Fractional density of the
outcomes plotted against their model predictions.
Confidence intervals were generated by boot-
strapping with replacement. Bottom: LOESS fit of
the actual outcomes against the model predictions;
narrow confidence bands confirm good prediction
accuracy.
(F) CoxPHmodels of stage and tumor type (‘‘Tissue’’)
with (full model) or without (reduced model) the
validation set predictions of the elastic net model
were compared; the full model significantly out-
performed the reduced model in all comparisons
(p < 0.001; false discovery rate (FDR) BH-corrected).
See also Figure S3.
(Figure 3F) improved predictive accuracy,
highlighting the importance of the immune
TME in determining survival. Lymphocyte
expression signature, high number of
unique TCR clonotypes, cytokines made
by activated Th1 and Th17 cells, and M1
macrophages most strongly associated with improved OS (Fig-
ure S3E), while wound healing, macrophage regulation, and
TGF-b associated with worse OS, recapitulating survival associ-
ations in immune subtypes. Within tumor types, the prognostic
implications of immune subtypes seen in univariate analyses
were largely maintained, with C3 correlating with better OS in
six tumor types and C4 with poor OS in three cancer types
(Figure S3F).
Immune Response Correlates of Somatic Variation
The immune infiltrate was related to measures of DNA damage,
including copy number variation (CNV) burden (both in terms of
number of segments and fraction of genome alterations),
aneuploidy, loss of heterozygosity (LOH), homologous recombi-
nation deficiency (HRD), and intratumor heterogeneity (ITH) (Fig-
ure 4A). LF correlated negatively with CNV segment burden, with
strongest correlation in C6 and C2, and positively with
aneuploidy, LOH, HRD, and mutation load, particularly in C3.
These results suggest a differential effect of multiple smaller,





Figure 4. Immune Response and Genome State
(A) Correlation of DNA damage measures (rows) with LF. From left to right: all TCGA tumors; averaged over tumor type; grouped by immune subtype.
(B) LF association with copy number (CN) alterations. Left: Differences between observed and expected mean LF in tumors with amplifications, by genomic
region. Significant (FDR < 0.01) differences in mean LF are marked with black caps on the profiles. Right: Same, for deletions.
(legend continued on next page)
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focal copy number events versus larger events on immune infil-
tration in certain immune subtypes.
Specific SCNAs affected LF and immune composition (Figures
4B and S4A). Chromosome 1p (including TNFRS9 and VTCN1)
amplification associated with higher LF, while its deletion did
the opposite. 19q deletion (including TGFB1) also correlated
with lower LF, consistent with the role of TGF-b in immune cell
recruitment (Bierie and Moses, 2010). Amplification of chr2,
20q, and 22q (including CTLA4, CD40, and ADORA2, respec-
tively), and deletions of 5q, 9p, and chr19 (including IL13 and
IL4, IFNA1 and IFNA2, and ICAM1, respectively) associated
with changes in macrophage polarity (Figure S4A). IL-13 influ-
ences macrophage polarization (Mantovani et al., 2005),
implying a possible basis for our observation that IL-13 deletions
associated with altered M0 macrophage fractions.
Increased ITH associates with worse clinical outcomes
or lower efficacy of IM therapy in a number of cancer types
(McGranahan et al., 2016; Morris et al., 2016). ITH correlated
(Spearman, Benjamini-Hochberg [BH]-adjusted p < 0.05) with
total LF in nine tumor types (LUAD, BRCA, KIRC, HNSC, GBM
[glioblastoma multiforme], OV, BLCA, SKCM, and READ; data
not shown) and with individual relative immune cell fractions in
many tumor types (Figure S4B). ITH was highest in C1 and
C2 (p < 10!229 relative to all others) and lowest in C3 (p = 3 3
10!5, Figure 1C), possibly supporting the link between lower
ITH and improved survival.
We correlated mutations in 299 cancer driver genes with im-
mune subtypes and found 33 significant associations (q < 0.1)
(Figure 4C, Table S2). C1 was enriched in mutations in driver
genes, such as TP53, PIK3CA, PTEN, or KRAS. C2 was enriched
in many of these genes, as well as HLA-A and B and CASP8,
which could be immune-evading mechanisms (Rooney et al.,
2015). C3 was enriched in BRAF, CDH1, and PBRM1mutations,
a finding of note since patients with PBRM1 mutations respond
particularly well to IM therapy (Miao et al., 2018). C4was enriched
in CTNNB1, EGFR, and IDH1 mutations. C5 was enriched in
IDH1, ATRX, and CIC, consistent with its predominance of LGG
samples. C6 was only enriched in KRAS G12 mutations. Muta-
tions in 23 driver genes associated with increased LF either in
specific tumor types or across them, including TP53, HLA-B,
BRAF, PTEN, NF1, APC, and CASP8. Twelve other events were
associated with lower LF, including the IDH1 R132H mutation,
GATA3, KRAS, NRAS, CTNNB1, and NOTCH1 (Figure 4D).
Since driver mutations in the same pathway had opposing
correlations with LF (e.g., BRAF, KRAS, NRAS), we considered
the overall effect of somatic alterations (mutations and SCNAs)
on eight oncogenic signaling pathways. PI3K, NOTCH, and
RTK/RAS pathway disruptions showed variable, tumor type-
specific effects on immune factors, while TGF-b pathway disrup-
tions more consistently associated with lower LF (most promi-
nently in C2 and C6; Figure S4C), higher eosinophils (C2), and
increased macrophages. However, in C3, TGF-b pathway
disruption associated with higher LF and M1 macrophages
and lower memory B cells, helper T cells, and M0 macrophages.
Thus, TGF-b pathway disruption has context-dependent effects
on LF but may promote increased macrophages, particularly
M1. Higher M1/M2 ratio, in turn, may reiterate the local pro-
inflammatory state in these patients.
Immune Response Correlates of Demographic and
Germline Variation
Immune cell content and expression of PD-L1 varied by gender
and genetic ancestry (Figures 4E and S4D). PD-L1 expression
was greater (p < 0.05, Kruskal-Wallis test, unadjusted) in women
than inmen inHNSC, KIRC, LUAD, THCA, andKIRP (Figure S4E),
while mesothelioma (MESO) showed an opposite trend. PD-L1
expression was lower in individuals of predicted African ancestry
(overall p = 5 3 10!6). This association was consistent across
most cancer types and was significant (p < 0.05, unadjusted) in
BRCA, COAD, HNSC (Figure S4F), and THCA. No single cis-
eQTL significantly correlated with PD-L1 expression, although
the SNP rs822337, approximately 1 kb upstream of CD274
transcription start, correlated weakly (p = 0.074; 1.3 3 10!4 un-
adjusted; Figure S4G). Lymphocyte fractions tended to be lower
in people of Asian ancestry, particularly in UCEC (uterine corpus
endometrial carcinoma) and BLCA (Figure S4H). The signifi-
cance of these demographic associations remains unclear but
provides hypotheses for the efficacy of checkpoint inhibitor
therapy based on genetic ancestry.
Survey of Immunogenicity
Peptides predicted to bind with MHC proteins (pMHCs) and
induce antitumor adaptive immunity were identified from SNV
and indel mutations. The number of pMHCs (neoantigen load)
varied between immune subtypes (Figure 1C), correlated posi-
tively with LF in most immune subtypes (Figure S4I), and trended
positive in most TCGA tumor subtypes, with some negative cor-
relation seen among GI subtypes, and differential trending seen
among individual LUAD, LUSC, OV, and KIRP subtypes (Fig-
ure S4J). Neoantigen load also associated with higher content
of CD8 T cells, M1 macrophages, and CD4 memory T cells,
and lower Treg, mast, dendritic, and memory B cells in multiple
tumor types (Figure S4K).
Most SNV-derived peptides which bind to MHC were each
found in the context of a single MHC allele (89.9%). Single
mutations generate 99.8% of unique pMHCs while 0.2% result
from distinct mutations in different genetic loci yielding identical
peptides (Figure 5A). The most frequently observed pMHCs
(C) Enrichment and depletion of mutations in driver genes and oncogenic mutations (OM) within immune subtypes, displayed as fold enrichment. Significance
was evaluated by the Cochran-Mantel-Haenszel c2 test, to account for cancer type (white, no significant association).
(D) Volcano plot showing driver genes and OMs associated with changes in LF, across all tumors (‘‘Pancan’’) and within specific tumor types as indicated. x axis:
Multivariate correlationwith LF (B-factor), taking into account tumor type and number ofmissensemutations. Values > 0 represent positive correlation with LF and
vice versa; y axis: !log10(p). Significant events (FDR < 0.1; p < 0.003) are in orange, others in gray.
(E) Left: Degree of association between gender for eight selected immune characteristics (rows) within TCGA tumor types (columns). Blue denotes a higher value
in women than in men, and red the opposite. Right: Degree of association between the immune characteristics and the first principal component of genetic
ancestry in TCGA participants (PC1), reflecting degree of African ancestry. Blue reflects lower values in individuals of African descent.
See also Figure S4 and Table S2.




Figure 5. The Tumor-Immune Interface
(A) Distribution of the number of pMHCs associated with number of mutations; the 4 pMHCs derived from > 40 mutations are labeled.
(B) Numbers of tumors expressing shared pMHCs. The known cancer genes from which the most frequent pMHCs in the population are derived are indicated.
(C) BCR (top) and TCR (bottom) diversity measured by Shannon entropy and species richness, logarithmically transformed, and expressed as Z-scores, for
immune subtypes.
(D and E) Co-occurrence of CDR3a-CDR3b (D) and pMHC-CDR3 pairs (E) as a surrogate marker for shared T cell responses. Pairs found in at least two samples
and meeting statistical significance are plotted, with jitter. x and y axes indicate how exclusive the pair members are: pairs in the top right typically co-occur,
whereas along the axes each member is more often found separately. Size of the circle indicates how many samples that pair was found in.
See also Figure S5 and Tables S3, S4, and S5.
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were from recurrently mutated genes (BRAF, IDH1, KRAS, and
PIKC3A for SNVs, TP53 and RNF43 for indels) (Figure 5B, Tables
S3 and S4). In BRCA and LIHC, worse PFI was associated with
higher neoantigen load, while BLCA and UCEC showed the
opposite effect (Figure S5A). For most tumors, however, there
were no clear associations between predicted pMHC count
and survival. Within immune subtypes (Figure S5B), higher neo-
antigen load was associated with improved PFI in C1 and C2 and
worse PFI in C3, C4, and C5. These results suggest that
neoantigen load providesmore prognostic information within im-
mune subtypes than based on tissue of origin, emphasizing the
importance of overall immune signaling in responding to tumor
neoantigens.
Cancer testis antigens (CTA) overall expression, and that of in-
dividual CTAs, varied by immune subtype with C5 having the
highest (p < 10!13) and C3 the lowest (p = 10!4) expression
values (Figure 1C). CEP55, TTK, and PBK were broadly ex-
pressed across immune subtypes, with enrichment in C1 and
C2. C5 demonstrated high expression of multiple CTAs, illus-
trating that CTA expression alone is insufficient to elicit an
intratumoral immune response.
We found human papilloma virus (HPV) in 6.2% of cases,
mainly in CESC, GBM, HNSC, and KIRC, whereas hepatitis B
virus (HBV) and Epstein-Barr virus (EBV) were mainly found in
LIHC and STAD (stomach adenocarcinoma), respectively. In a
regressionmodel of all tumors, high load of each virus type asso-
ciated with immune features (Figure S5C, cancer-type adjusted).
High EBV content associated strongly with high CTLA4 and
CD274 expression and low B cell signatures. High HPV levels
associated with increased proliferation and Th2 cells but low
macrophage content. In contrast, high HBV levels associated
with Th17 signal and gd T cell content. These findings highlight
the diverse effect of different viruses on the immune response
in different cancer types.
Our findings suggest that pMHC burden and viral content
impact immune cell composition, while CTAs have inconsistent
effects on the immune response. Moreover, the effect of
pMHC load on prognosis is disease specific and influenced by
immune subtype.
The Adaptive Immune Receptor Repertoire in Cancer
Antigen-specific TCR and BCR repertoires are critical for recog-
nition of pathogens and malignant cells and may reflect a robust
anti-tumor response comprising a large number of antigen-
specific adaptive immune cells that have undergone clonal
expansion and effector differentiation.
We evaluated TCR a and b and immunoglobulin heavy and
light chain repertoires from RNA-seq. Mean TCR diversity values
differed by immune subtype, with the highest diversity in C6 and
C2 (p<10!183,Wilcoxon, relative to all other subtypes; Figure 5C)
and by tumor type (Figure S5D, lower panel). We saw recurrent
TCR sequences across multiple samples (Figure S5E, Table
S5), suggesting a common, but not necessarily cancer-related,
antigen (the top recurrent TCRs include known mucosal associ-
ated invariant T cell sequences). We assessed co-occurrence of
complementarity determining region 3 (CDR3) a and b chains, in
order to determine the frequency of patients with identical TCRs
(a surrogate marker for shared T cell responses). We identified
2,812 a-b pairs present in at least 2 tumors (p % 0.05, Fisher’s
exact test with Bonferroni correction; Figure 5D and Table S5).
Likewise, testing for co-occurrence of specific SNV pMHC-
CDR3 pairs across all patients identified 206 pMHC-CDR3 a
pairs and 196 pMHC-CDR3 b pairs (Figure 5E, Table S5). Thus,
a minority of these patients appear to share T cell responses,
possibly mediated by public antigens. That said, there is rela-
tively little pMHC and TCR sharing among tumors, highlighting
the large degree of diversity in TILs.
Higher TCR diversity only correlated with improved PFI in a
few tumor types (BLCA, COAD, LIHC, and UCEC) (Figure S5F).
Therefore, it may be more important for the immune system to
mount a robust response against only a few antigens, than a
diverse response against many different antigens.
The pattern of immunoglobulin heavy chain diversity was
similar to that of TCR diversity (Figures 5C and S5D), with tumors
showing significant variance in IgH repertoire diversity, suggest-
ing differential B cell recruitment and/or clonal expansion within
the tumor types.
Regulation of Immunomodulators
IMs are critical for cancer immunotherapy with numerous IM ag-
onists and antagonists being evaluated in clinical oncology (Tang
et al., 2018). To advance this research, understanding of their
expression and modes of control in different states of the TME
is needed. We examined IM gene expression, SCNAs, and
expression control via epigenetic and miRNA mechanisms.
Gene expression of IMs (Table S6, Figure 6A) varied across im-
mune subtypes, and IM expression largely segregated tumors by
immune subtypes (Figure S6A), perhaps indicative of their role in
shaping the TME. Genes with the greatest differences between
subtypes (Figures 6B and S6B) included CXCL10 (BH-adjusted
p < 10!5), most highly expressed in C2 (consistent with its known
interferon inducibility) and EDNRB (BH-adjusted p < 10!5), most
highly expressed in the immunologically quiet C5. DNA methyl-
ation of many IM genes, e.g., CD40 (Figure 6C), IL10, and
IDO1, inversely correlated with gene expression, suggesting
epigenetic silencing. 294 miRNAs were implicated as possible
regulators of IM gene expression; among these, several associ-
ated with IMs in multiple subtypes (Figure S6C) including
immune inhibitors (EDNRB, PD-L1, and VEGFA) and activators
(CD28 and TNFRSF9). The immune activator BTN3A1 was one
of the most commonly co-regulated IMs from the SYGNAL-
PanImmune network (below). Negative correlations between
miR-17 and BTN3A1, PDCD1LG2, and CD274 may relate to
the role of this miRNA in maturation and activation of cells into
effector or memory subsets (Liang et al., 2015).
Copy-number alterations affected multiple IMs and varied
across immune subtypes. C1 and C2 showed both frequent
amplification and deletion of IM genes, consistent with their
greater genomic instability, while subtypes C3 and C5 generally
showed fewer alterations in IMgenes. In particular, IMsSLAMF7,
SELP, TNFSF4 (OX40L), IL10, and CD40 were amplified less
frequently in C5 relative to all samples, while TGFB1, KIR2DL1,
and KIR2DL3 deletions were enriched in C5 (Figure 6D), consis-
tent with our observation of lower immune infiltration with TGFB1
deletion (Figure S4A). CD40 was most frequently amplified in C1
(Figure 6D) (Fisher’s exact p < 10!10 for all comparisons
mentioned). Overall, these marked differences in IM copy
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Figure 6. Regulation of Immunomodulators
(A) From left to right: mRNA expression (median normalized expression levels); expression versusmethylation (gene expression correlation with DNA-methylation
beta-value); amplification frequency (the difference between the fraction of samples in which an IM is amplified in a particular subtype and the amplification
fraction in all samples); and the deletion frequency (as amplifications) for 75 IM genes by immune subtype.
(B) Distribution of log-transformed expression levels for IM genes with largest differences across subtypes (by Kruskal-Wallis test).
(C) CD40 expression is inversely correlated to methylation levels (Affymetrix 450K probe cg25239996, 125 bases upstream of CD40 TSS) in C3. Each point
represents a tumor sample, and color indicates point density.
(D) Proportion of samples in each immune subtype with copy number alterations in CD40 (top) and KIR2DL3 (bottom). The ‘‘All’’ column shows the overall
proportion (8,461 tumors).
See also Figure S6 and Table S6.





Figure 7. Predicted Networks Modulating the Immune Response to Tumors
TME estimates and tumor cell characteristics were combined with available data on possible physical, signaling, and regulatory interactions to predict cellular
and molecular interactions involved in tumoral immune responses.
(legend continued on next page)
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number may be reflective of more direct modulation of the TME
by cancer cells.
Among IMs under investigation for cancer therapy, expression
of VISTA is relatively high in all tumor types and highest in
MESO; BTLA expression is high in C4 and C5; HAVCR2
(TIM-3) shows evidence of differential silencing among immune
subtypes; and IDO1 is amplified, mostly in C1. The observed
differences in regulation of IMs might have implications for ther-
apeutic development and combination immune therapies, and
the multiple mechanisms at play in evoking them further high-
lights their biological importance.
Networks Modulating Tumoral Immune Response
The immune response is determined by the collective states
of intracellular molecular networks in tumor, immune, and
other stromal cells and the extracellular network encompassing
direct interaction among cells and communication via soluble
proteins such as cytokines to mediate interactions among
those cells.
Beginning with a large network of extracellular interactions
known from other sources, we identified which of those met
a specified precondition for interaction, namely that both
interaction partners are consistently present within samples
in an immune subtype, according to our TME estimates. We
focused the network on IMs. Networks in C2 and C3 had
abundant CD8 T cells, while C3, C4, and C6 were enriched
in CD4 T cells.
A small sub-network (Figure 7A), focused around IFN-g, illus-
trates some subtype-specific associations. In both C2 and C3,
CD4 T cells, CD8 T cells, and NK cells correlated with expression
of IFNG and CCL5, a potent chemoattractant. A second sub-
network (Figure 7B), centered on TGF-b, was found in the C2,
C3, and C6 networks. Across subtypes, different cell types
were associated with abundant expression of TGFB1: CD4
T cells and mast cells in C3 and C6, macrophages in C6, neutro-
phils and eosinophils in C2 and C6, and B cells, NK cells, and
CD8 T cells in C2 and C3. The receptors known to bind TGF-b
likewise were subtype specific and may help mediate the
TGF-b-driven infiltrates, with TGFBR1, 2, and 3 found only in
the C3 and C6 networks. These results largely echo findings
seen in our TGF-b pathway analysis (Figure S4C), which exam-
ined the effects of intracellular, rather than extracellular,
signaling disruption on immune TME composition across im-
mune subtypes. Finally, a third cytokine subnetwork illustrates
variation in T cell ligands and receptors across immune subtypes
(Figure 7C). CD4 and CD8 receptors fell into two groups, those
found in C2, C3, and C6 networks, such as PDCD1, and those
absent in C3, such as IL2RA and LAG3. Some T cell-associated
ligands were subtype specific, such as CD276 (C2, C6), IL1B
(C6), and VEGFB (C4).
The derived extracellular networks reflect the properties of
immune subtypes in terms of cellular propensities and immune
pathway activation noted earlier (Figures 1B, 1C, 2A, and S2A),
but also place those properties in the context of possible interac-
tions in the TME that may play a role in sculpting those same
properties. The particular associations observed among IMs
within distinct subtypes may be important for identifying direc-
tions for therapy.
We next used two complementary approaches, master regu-
lators (MRs) and SYGNAL, to synthesize a pan-cancer tran-
scriptional regulatory network describing the interactions
linking genomic events to transcriptional regulators to down-
stream target genes, and finally to immune infiltration and pa-
tient survival. In both approaches, somatic alterations were
used as anchors to infer regulatory relationships, in that they
can act as a root cause of the ‘‘downstream’’ transcriptional
changes mediated through transcription factors (TFs) and
miRNAs.
This resulted in two transcriptional networks. The first one,
MR-PanImmune, consisted of 26 MRs that acted as hubs asso-
ciated with observed gene expression and LF, connected with
15 putative upstream driver events (Figure 7D). The second
(A) Immune subtype-specific extracellular communication network involving IFN-g (IFNG, bottom of the diagram), whose expression is concordant with that of its
cognate receptors IFNGR1 and IFNGR2 (bottom right and left, respectively), in C2 andC3 (yellow and green arrows, respectively; line thickness indicates strength
of association). NK cells (left), which are known to secrete IFN-g, could be producing IFN-g in C2 and C3, as the NK cellular fraction is concordant with IFNG
expression in both. CXCR3 is known to be expressed on NK cells and has concordant levels, but only in C3 (green arrow). This is a subnetwork within a larger
network constructed by similarly combining annotations of known interactions between ligands, receptors, and particular immune cells types, with evidence for
concordance of those components.
(B) TGF-b subnetwork. Magenta: C6.
(C) T cell subnetwork.
(D) Master Regulator (MR)-Pan-Immune Network. The network diagram shows 26 MR ‘‘hubs’’ (filled orange) significantly associated with 15 upstream driver
events (orange rings), along with proteins linking the two. The lineage factor VAV1 (on left) is inferred to be aMR by combining predicted protein activity with data
on gene expression, protein interactions, and somatic alterations. VAV1 activity correlates with LF (degree of correlation depicted as degree of orange). Mutations
in HRAS (center of network) are statistically associated with changes in LF. The HRAS and VAV1 proteins are in close proximity on a large network of known
protein-protein interactions (not shown), as both can lead to activation of protein MAP2K1, (as shown connecting with dotted lines). Mutations in HRAS are
associated (p < 0.05) with VAV1 activity, and their link through documented protein interactions implies that HRAS could directly modulate the activity of VAV1. In
the diagram, the size of MR nodes represents their ranked activity. Smaller nodes with red borders represent mutated and/or copy-number altered genes
statistically associated with one or more MR and LF, with the thickness of the border representing the number of associated MRs; small gray nodes are ‘‘linker’’
proteins.
(E) Regulators of immune subtypes from SYGNAL-PanImmune Network. Tumor types (octagons) linked through mutations (purple chevrons) to transcription
factors (TFs, red triangles) and miRNAs (orange diamonds) that actively regulate the expression of IMs in biclusters associated with a single immune subtype
(circles). The network describes predicted causal and mechanistic regulatory relationships linking tumor types through their somatic mutations (yellow edges)
which causally modulate the activity of TFs and/or miRNAs (purple edges), which in turn regulate genes (not shown) whose expression is associated with an
immune subtype (red edges). For example, RB1 mutations in LIHC (5% of patients) have significant evidence for causally modulating the activity of PRDM1
which in turn regulates genes associated (causalmodel at least 3 times as likely as alternative models and p value < 0.05) with C1 andC2. Interactions for this path
are bolded.
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one, SYGNAL-Panimmune, comprised 171 biclusters enriched
in IMs and associated with LF.
Seven TFs were shared between the MR- and SYGNAL-Pan-
Immune networks, a significant overlap (p = 4.83 10!10, Fisher’s
exact test): PRDM1, SPI1, FLI1, IRF4, IRF8, STAT4, and
STAT5A. Additional MRs included the hematopoietic lineage
specific factor IKZF1, which may reflect variation in immune
cell content, and known IMs, such as IFNG, IL16, CD86, and
TNFRSF4. The regulators in SYGNAL-PanImmune were inferred
to regulate a total of 27 IM genes (Figure S7C). The top two most
commonly co-regulated IMs from SYGNAL-PanImmune,
BTN3A1 and BTN3A2, are of particular interest as they modulate
the activation of T cells (Cubillos-Ruiz et al., 2010) and have anti-
body-based immunotherapies (Benyamine et al., 2016; Legut
et al., 2015).
Somatic alterations in AKAP9, HRAS, KRAS, and PREX2
were inferred to modulate the activity of IMs according to
both the MR- and SYGNAL-PanImmune, a significant overlap
(p = 1.6 3 10!7, Fisher’s exact test). In MR-PanImmune,
MAML1 and HRAS had the highest number of statistical inter-
actions with 26 MRs. This analysis identified complex roles for
the RAS-signaling pathway (Figure 7D) specifically through
connections to lineage factor VAV1 (implicated in multiple hu-
man cancers), potentially mediated by MAP2K1. Similarly,
MAML1, hypothesized to mediate cross-talk across pathways
in cancer (McElhinny et al., 2008), was associated (p % 0.05)
with multiple MRs, including STAT1, STAT4, CIITA, SPI1,
TNFRSF4, CD86, VAV1, IKZF1, and IL16.
In SYGNAL-PanImmune, some regulators of IMs, but not up-
stream somatic mutations, were shared between tumor types,
including STAT4, which regulated BTN3A1 and BTN3A2 in
both LUSC and UCEC, secondary to implied causal mutations
TP53 and ARHGAP35, respectively. Conversely, causal muta-
tions shared across tumor types may associate with different
tumor-specific downstream regulators. TP53 was a causal
mutation in UCEC acting through IRF7 to regulate many of the
same IMs as was seen in LUSC. These differences in causal re-
lationships arise because the different cell types giving rise to
each tumor type affect oncogenic paths.
We identified the putative regulators of immune gene expres-
sion within immune subtypes (Figure 7E). In these predictions,
C1-associated biclusters were regulated by ERG, KLF8,
MAFB, STAT5A, and TEAD2. C1 and C2 shared regulation by
BCL5B, ETV7, IRF1, IRF2, IRF4, PRDM1, and SPIB, consistent
with IFN-g signaling predominance in these subtypes. C3 was
regulated by KLF15 and miR-141-3p. C6-associated biclusters
were regulated by NFKB2. C1, C2, and C6 shared regulation
by STAT2 and STAT4, implying shared regulation by important
immune TF families, such as STAT and IRF, but also differential
employment of subunits and family members by the immune
milieu.
In SYGNAL-PanImmune, the increased expression of
biclusters enriched with IMs from KIRC, LGG, LUSC, and
READ was associated with worse patient survival (CoxPH
BH adjusted p value % 0.05). Conversely, the increased
expression of biclusters enriched with IMs from SKCM, con-
taining CCL5, CXCL9, CXCL10, HAVCR2, PRF1, and MHC
class II genes, were associated with improved patient survival
(BH-adjusted p % 0.05).
DISCUSSION
We report an extensive evaluation of immunogenomic features in
more than 10,000 tumors from 33 cancer types. Data and results
are available as Supplemental Tables, at NCI GDC, and interac-
tively at the CRI iAtlas portal, which is being configured to accept
new immunogenomics datasets and feature calculations as they
come available, including those derived from immunotherapy
clinical trials, to develop as a ‘‘living resource’’ for the immunoge-
nomics community. Meta-analysis of consensus expression
clustering revealed immune subtypes spanning multiple tumor
types and characterized by a dominance of either macrophage
or lymphocyte signatures, T-helper phenotype, extent of intratu-
moral heterogeneity, and proliferative activity. All tumor samples
were assessed for immune content by multiple methods. These
include the estimation of immune cell fractions from deconvolu-
tion of gene expression and DNA methylation data, prediction of
neoantigen-MHC pairs from mutations and HLA-typing, and
evaluation of BCR and TCR repertoire from RNA-sequencing
data. Immune content was compared among immune and
cancer subtypes, and somatic alterations were identified that
correlate with changes in the TME. Finally, predictions were
made of regulatory networks that could influence the TME, and
intracellular communication networks in the TME, based on
integrating known interactions and observed associations. Im-
munogenomic features were predictive of outcome, with OS
and PFI differing between immune subtypes both within and
across cancer types.
C4 and C6 subtypes conferred the worst prognosis on their
constituent tumors and displayed composite signatures reflect-
ing a macrophage dominated, low lymphocytic infiltrate, with
high M2 macrophage content, consistent with an immunosup-
pressed TME for which a poor outcome would be expected. In
contrast, tumors included in the two subtypes displaying a
type I immune response, C2 and C3, had the most favorable
prognosis, consistent with studies suggesting a dominant
type I immune response is needed for cancer control (Galon
et al., 2013). In addition, C3 demonstrated the most pro-
nounced Th17 signature, in agreement with a recent systematic
review suggesting that Th17 expression is generally associated
with improved cancer survival (Punt et al., 2015). C2 was IFN-g
dominant and showed a less favorable survival despite having
the highest lymphocytic infiltrate, a CD8 T cell-associated
signature, and highest M1 content, suggesting a robust anti-tu-
mor immune response. One explanation for this discrepancy is
the aggressiveness of both the tumor types and specific cases
within C2 relative to C3. C2 showed the highest proliferation
signature and ITH while C3 was the lowest in both those cate-
gories. It may be that the immune response simply could not
control the rapid growth of tumors comprising C2. A second
hypothesis is that tumors in C2 are those that have already
been remodeled by the existing robust type I infiltrate and
have escaped immune recognition. While signatures biased
toward interferon-mediated viral sensing and antigen presenta-
tion genes were often associated with higher survival, interferon
signatures without increased antigen presentation showed an
opposite association. Loss of genes associated with antigen
processing and presentation is often found in tumors that
have been immune edited. In contrast to the potential immune
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editing of C2, C3 may represent immunologic control of dis-
ease, that is, immune equilibrium.
Possible impact of somatic alterations on immune response
was seen. For example, KRAS mutations were enriched in C1
and but infrequent in C5, suggesting that mutations in driver
oncogenes alter pathways that affect immune cells. Driver muta-
tions such as TP53, by inducing genomic instability, may alter the
immune landscape via the generation of neoantigens. Our find-
ings confirmed previous work showing that mutations in BRAF
(Ilieva et al., 2014) enhance the immune infiltrate while those in
IDH1 diminish it (Amankulor et al., 2017). Further work is needed
to determine the functional aspects of these associations.
Tumor-specific neoantigens are thought to be key targets of
anti-tumor immunity and are associated with improved OS and
response to immune checkpoint inhibition in multiple tumor
types (Brown et al., 2014). We found OS correlated with pMHC
number in only a limited number of tumors, with no clear associ-
ation in most tumors, including several responsive to immune
checkpoint inhibitor therapy. There are some caveats to this
finding. The current predictors are highly sensitive but poorly
specific for neoantigen identification, and our approach did not
include neoantigens from introns or spliced variants. Moreover,
it is not possible to fully determine the ability to process and
present an epitope or the specific T cell repertoire in each tumor,
which impacts the ability to generate a neoantigen response. It is
also possible that the role of neoantigens may vary with tumor
type, as supported by our per-tumor results.
Integrative methods predicted tumor-intrinsic and tumor-
extrinsic regulation in, of, and by the TME and yielded informa-
tion on specific modes of intracellular and extracellular control,
the latter reflecting the network of cellular communication
among immune cells in the TME. The resulting network was
rich in structure, with mast cells, neutrophils, CD4 T cells, NK
cells, B cells, eosinophils, macrophages, and CD8 T cells
figuring prominently. The cellular communication network high-
lighted the role of key receptor and ligands such as TGFB1,
CXCL10, and CXCR3 and receptor-ligand pairs, such as the
CCL5-CCR5 axis, and illustrated how immune cell interactions
may differ depending on the immune system context, mani-
fested in the immune subtype.
Predicted intracellular networks implied that seven immune-
related TFs (including interferon and STAT-family transcription
factors) may play an active role in transcriptional events related
to leukocyte infiltration, and that mutations in six genes
(including Ras-family proteins) may influence immune infiltra-
tion. Across tumor types, the TFs and miRNAs regulating the
expression of IMs tended to be shared, while somatic
mutations modulating those regulatory factors tended to differ.
This suggests that therapies targeting regulatory factors up-
stream of IMs should be considered and that they may have
a broader impact across tumor types than therapies focusing
on somatic mutations. Of note, in these approaches, it is not
always possible to fully ascertain whether some particular
interaction acts in the tumor, immune, or stromal cell compart-
ments, but this could be improved on by incorporating
additional cell-type-specific knowledge. Shared elements of
intra- and extracellular network models should also be
explored, with particular regard to the IMs and cytokines
in both.
There are important caveats to using TCGA data. First, sur-
vival event rates and follow-up durations differ across the tu-
mor types. Second, for most tumor types, samples with less
than 60% tumor cell nuclei by pathologist review were
excluded from study, thus potentially removing the most im-
mune-infiltrated tumors from analysis. The degree to which
this biases the results, relative to the general population of
cancer patients, is difficult to ascertain. Our analyses were
also limited by restriction to data from genome-wide molecular
assays, in the absence of targeted classical cellular immu-
nology assays for confirming cell phenotype distribution, as
those types of data have not been collected from TCGA
patients.
In summary, six stable and reproducible immune subtypes
were found to encompass nearly all human malignancies.
These subtypes were associated with prognosis, genetic, and
immune modulatory alterations that may shape the specific
types of immune environments we have observed. With our
increasing understanding that the tumor immune environment
plays an important role in prognosis as well as response to
therapy, the definition of the immune subtype of a tumor may
play a critical role in the predicting disease outcome as
opposed to relying solely on features specific to individual can-
cer types.
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